Shopping Cart

There are no products in your cart.

Prof. Andrew Scott AM

HEAD, TUMOUR TARGETING PROGRAM | HEAD, TUMOUR TARGETING LABORATORY | DIRECTOR, DEPARTMENT OF MOLECULAR IMAGING AND THERAPY, AUSTIN HEALTH

More about Prof. Andrew Scott AM

Throughout my research career as a translational clinician-scientist, I have had an abiding interest in the mechanisms of tumour cell growth, as well as the development of innovative strategies to improve diagnosis and therapy for cancer patients.

My major research focus areas have been in defining and characterising antigen and receptor targets for cancer therapy, signaling and metabolic pathways in cancer cells, antibody-based therapy and immune regulation of tumours, and molecular imaging of cancer.

I have developed a program to translate our laboratory discoveries to use in the clinic, which has so far led to 10 novel antibodies and recombinant proteins progressing successfully through first-in-human, Phase I and II cancer trials. This program has delivered several key outcomes, including 21 patents and the licensing of seven discoveries to Pharma and Biotech.

I have published over 330 peer-reviewed papers and 22 book chapters, principally in the areas of oncology and molecular imaging. My invited reviews in leading journals include Nature Reviews Cancer, Nature Reviews Clinical Oncology and Cancer Research.

I am actively involved in the training and mentoring of young scientists and clinicians, and am currently supervising several doctoral students in addition to postdoctoral fellows and Nuclear Medicine trainees.

In addition to my research and clinical activities, I am engaged in strategic planning for training, health care policy, and molecular imaging and nuclear medicine therapy advocacy within the US, European, South American, Asia-Oceania, and African regions, as well as with the IAEA and WHO. I am former President of the World Federation of Nuclear Medicine and Biology, the peak global Nuclear Medicine organisation.

My national leadership roles include being a founding Board member and the current Chair of Cancer Trials Australia, as well as a Board member of the Australian Nuclear Science and Technology Organisation (ANSTO) since 2007. I also participate in policy and governance activities with the Australian Government.

Education

Bachelor of Medicine and Bachelor of Surgery (Honours), University of Sydney, Australia

Doctor of Medicine, University of Sydney, Australia

Fellowship, Royal Australasian College of Physicians

Fellowship, Australasian Association of Nuclear Medicine Specialists

Fellow, Australian Institute of Company Directors

DDU, Australasian Society for Ultrasound in Medicine

ECFMG, certified for US practice

Fellowship, Memorial Sloan-Kettering Cancer Center

Current Appointments

Head, Tumour Targeting Program and Laboratory, Olivia Newton-John Cancer Research Institute

Director, Department of Molecular Imaging and Therapy, Austin Health, Melbourne

Professor, School of Cancer Medicine, La Trobe University

Professor, Department of Medicine, University of Melbourne

Achievements

Member, Order of Australia (AM) - for significant service to nuclear medicine and cancer research as an academic, and to professional organisations.

Medical Board Traveling Fellowship, Royal North Shore Hospital, Sydney, Australia

Elected Fellow, Australian Academy of Health and Medical Sciences, 2017

Gammasonics Award, Australian and New Zealand Society of Nuclear Medicine, 2016

Distinguished Scientist Award, Austin Medical Research Foundation, 2014

Journal of Nuclear Medicine Editors Choice Award for best clinical manuscript, 2008

Inaugural Pioneer Award, Australian and New Zealand Society of Nuclear Medicine, 2005

Recent Publications

Ciprotti, M., N.C. Tebbutt, F.T. Lee, S.T. Lee, H.K. Gan, D.C. McKee, G.J. O'Keefe, S.J. Gong, G. Chong, W. Hopkins, B. Chappell, F.E. Scott, M.W. Brechbiel, A.N. Tse, M. Jansen, M. Matsumura, M. Kotsuma, R. Watanabe, R. Venhaus, R.A. Beckman, J. Greenberg, and A.M. Scott, Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol, 2015. 33(24): 2585-2587, 2015.
Burvenich IJ, Farrugia W, Lee FT, Catimel B, Liu Z, Makris D, Cao D, O'Keefe GJ, Brechbiel MW, King D, Spirkoska V, Allan LC, Ramsland PA, Scott AM. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. MAbs. 2016 May-Jun;8(4):775-86.
Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Mol Cancer Ther. 2018 Apr;17(4):795-805.
Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nat Med. 2018 May;24(4):463-473.
Li H, Zeitelhofer M, Nilsson I, Liu X, Allan L, Gloria B, Perani A, Murone C, Catimel B, Neville AM, Scott FE, Scott AM, Eriksson U. Development of monoclonal anti-PDGF-CC antibodies as tools for investigating human tissue expression and for blocking PDGF-CC induced PDGFRα signalling in vivo. PLoS One. 2018 Jul 27;13(7):e0201089.